← Back to Screener
Krystal Biotech, Inc. Common Stock (KRYS)
Price$301.00
Value ScoreD
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)30.15%
Price vs S&P 500 (4W)-1.53%
VGM Score59.32
Market Capitalization$8.87B
P/E Ratio (Annual)43.32x
All Metrics
P/CF (Annual)44.18x
Book Value / Share (Quarterly)$43.37
P/TBV (Annual)5.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$8.06
Price vs S&P 500 (YTD)13.93%
Gross Margin (TTM)94.17%
Net Profit Margin (TTM)53.92%
EPS (TTM)$7.48
10-Day Avg Trading Volume0.23M
EPS Excl Extra (TTM)$7.48
EPS (Annual)$6.84
ROI (Annual)16.80%
Gross Margin (Annual)94.08%
Cash / Share (Quarterly)$27.97
P/E Basic Excl Extra (TTM)39.43x
Revenue Growth QoQ (YoY)31.95%
P/E Normalized (Annual)43.32x
ROA (Last FY)15.36%
Revenue Growth TTM (YoY)25.15%
EBITD / Share (TTM)$6.13
ROE (5Y Avg)-2.18%
Operating Margin (TTM)42.81%
Cash Flow / Share (Annual)$6.47
P/B Ratio6.95x
P/B Ratio (Quarterly)5.96x
Net Income / Employee (Annual)$694,300
EV / Revenue (TTM)20.06x
Net Interest Coverage (TTM)-52.52x
ROA (TTM)17.62%
EPS Growth QoQ (YoY)53.27%
EV / EBITDA (TTM)45.38x
EPS Incl Extra (Annual)$6.84
Current Ratio (Annual)9.95x
Quick Ratio (Quarterly)8.82x
3-Month Avg Trading Volume0.28M
52-Week Price Return126.96%
EV / Free Cash Flow (Annual)44.32x
P/E Incl Extra (TTM)39.43x
Revenue / Employee (TTM)$1,414,600
Tangible BV / Share (Quarterly)$26.81
P/S Ratio (Annual)22.80x
Asset Turnover (Annual)0.29x
52-Week High$319.48
EPS Excl Extra (Annual)$6.84
CapEx CAGR (5Y)-4.24%
Tangible BV CAGR (5Y)60.21%
26-Week Price Return38.07%
Quick Ratio (Annual)9.28x
13-Week Price Return15.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.46x
Enterprise Value$8.37B
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)23.03%
Revenue / Employee (Annual)$1,319,100
Pretax Margin (Annual)48.69%
Cash / Share (Annual)$28.36
3-Month Return Std Dev35.90%
Net Income / Employee (TTM)$762,800
ROE (Last FY)16.80%
Net Interest Coverage (Annual)-9.83x
EPS Basic Excl Extra (Annual)$6.84
P/FCF (TTM)37.38x
Receivables Turnover (TTM)3.62x
EV / Free Cash Flow (TTM)35.27x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$7.48
ROI (TTM)19.25%
P/S Ratio (TTM)21.26x
Revenue / Share (Annual)$12.99
Tangible BV / Share (Annual)$20.27
Forward P/E35.46x
Price vs S&P 500 (52W)102.60%
P/E Ratio (TTM)39.43x
EPS Growth TTM (YoY)80.24%
Year-to-Date Return22.09%
5-Day Price Return0.97%
EPS Normalized (Annual)$6.84
ROA (5Y Avg)-2.21%
Net Profit Margin (Annual)52.64%
Month-to-Date Return-2.60%
Cash Flow / Share (TTM)$-0.95
EBITD / Share (Annual)$5.58
Operating Margin (Annual)41.45%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)35.45x
ROI (5Y Avg)-2.18%
P/E Excl Extra (TTM)39.43x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$7.48
P/TBV (Quarterly)3.84x
P/B Ratio (Annual)5.86x
Inventory Turnover (TTM)0.67x
Pretax Margin (TTM)49.68%
Book Value / Share (Annual)$41.78
Price vs S&P 500 (13W)7.37%
Beta0.57x
P/FCF (Annual)46.97x
Revenue / Share (TTM)$13.68
ROE (TTM)19.25%
52-Week Low$127.99
vGradeD
gGradeB
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 261.83est. 1.45
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.35
4.28
4.28
4.28
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $71.53 |
About
Krystal Biotech is a commercial-stage biotechnology company developing genetic medicines for diseases with high unmet medical needs using its proprietary HSV-1-based gene therapy platform. The company commercializes VYJUVEK, its lead therapeutic product, across the United States, European Union, and Japan. Krystal Biotech leverages its platform to create vectors that deliver therapeutic genes to target cells with exclusive rights to develop, manufacture, and commercialize VYJUVEK globally.